605 related articles for article (PubMed ID: 17763368)
1. Glypican-3 immunocytochemistry in liver fine-needle aspirates : a novel stain to assist in the differentiation of benign and malignant liver lesions.
Kandil D; Leiman G; Allegretta M; Trotman W; Pantanowitz L; Goulart R; Evans M
Cancer; 2007 Oct; 111(5):316-22. PubMed ID: 17763368
[TBL] [Abstract][Full Text] [Related]
2. Utility of glypican-3 and survivin in differentiating hepatocellular carcinoma from benign and preneoplastic hepatic lesions and metastatic carcinomas in liver fine-needle aspiration biopsies.
Nassar A; Cohen C; Siddiqui MT
Diagn Cytopathol; 2009 Sep; 37(9):629-35. PubMed ID: 19405109
[TBL] [Abstract][Full Text] [Related]
3. Glypican-3 expression in hepatocellular tumors: diagnostic value for preneoplastic lesions and hepatocellular carcinomas.
Wang XY; Degos F; Dubois S; Tessiore S; Allegretta M; Guttmann RD; Jothy S; Belghiti J; Bedossa P; Paradis V
Hum Pathol; 2006 Nov; 37(11):1435-41. PubMed ID: 16949914
[TBL] [Abstract][Full Text] [Related]
4. Distinction of hepatocellular carcinoma from benign hepatic mimickers using Glypican-3 and CD34 immunohistochemistry.
Coston WM; Loera S; Lau SK; Ishizawa S; Jiang Z; Wu CL; Yen Y; Weiss LM; Chu PG
Am J Surg Pathol; 2008 Mar; 32(3):433-44. PubMed ID: 18300806
[TBL] [Abstract][Full Text] [Related]
5. Diagnostic role of serum glypican-3 in differentiating hepatocellular carcinoma from non-malignant chronic liver disease and other liver cancers.
Tangkijvanich P; Chanmee T; Komtong S; Mahachai V; Wisedopas N; Pothacharoen P; Kongtawelert P
J Gastroenterol Hepatol; 2010 Jan; 25(1):129-37. PubMed ID: 19793164
[TBL] [Abstract][Full Text] [Related]
6. Arginase-1: a novel immunohistochemical marker of hepatocellular differentiation in fine needle aspiration cytology.
McKnight R; Nassar A; Cohen C; Siddiqui MT
Cancer Cytopathol; 2012 Aug; 120(4):223-9. PubMed ID: 22298472
[TBL] [Abstract][Full Text] [Related]
7. Expression and clinicopathologic significance of glypican 3 in hepatocellular carcinoma.
Yan B; Wei JJ; Qian YM; Zhao XL; Zhang WW; Xu AM; Zhang SH
Ann Diagn Pathol; 2011 Jun; 15(3):162-9. PubMed ID: 21371925
[TBL] [Abstract][Full Text] [Related]
8. Value of glypican 3 immunostaining in the diagnosis of hepatocellular carcinoma on needle biopsy.
Anatelli F; Chuang ST; Yang XJ; Wang HL
Am J Clin Pathol; 2008 Aug; 130(2):219-23. PubMed ID: 18628090
[TBL] [Abstract][Full Text] [Related]
9. Diagnostic utility of glypican-3 for hepatocellular carcinoma on liver needle biopsy.
Wang FH; Yip YC; Zhang M; Vong HT; Chan KI; Wai KC; Wen JM
J Clin Pathol; 2010 Jul; 63(7):599-603. PubMed ID: 20501450
[TBL] [Abstract][Full Text] [Related]
10. Glypican-3: a novel diagnostic marker for hepatocellular carcinoma and more.
Kandil DH; Cooper K
Adv Anat Pathol; 2009 Mar; 16(2):125-9. PubMed ID: 19550373
[TBL] [Abstract][Full Text] [Related]
11. Diagnostic utility of CD10 in differentiating hepatocellular carcinoma from metastatic carcinoma in fine-needle aspiration biopsy (FNAB) of the liver.
Lin F; Abdallah H; Meschter S
Diagn Cytopathol; 2004 Feb; 30(2):92-7. PubMed ID: 14755758
[TBL] [Abstract][Full Text] [Related]
12. Glypican-3 expression distinguishes small hepatocellular carcinomas from cirrhosis, dysplastic nodules, and focal nodular hyperplasia-like nodules.
Libbrecht L; Severi T; Cassiman D; Vander Borght S; Pirenne J; Nevens F; Verslype C; van Pelt J; Roskams T
Am J Surg Pathol; 2006 Nov; 30(11):1405-11. PubMed ID: 17063081
[TBL] [Abstract][Full Text] [Related]
13. [Significance of glypican-3 mRNA expression in hepatocellular carcinoma tissues and peripheral blood cells].
Li BD; Zhao QC; Zhu YT; Zhang FQ; Dou KF
Zhonghua Wai Ke Za Zhi; 2006 Apr; 44(7):458-62. PubMed ID: 16772080
[TBL] [Abstract][Full Text] [Related]
14. Glypican-3 as a potential differential diagnosis marker for hepatocellular carcinoma: a tissue microarray-based study.
Zhang L; Liu H; Sun L; Li N; Ding H; Zheng J
Acta Histochem; 2012 Oct; 114(6):547-52. PubMed ID: 22119409
[TBL] [Abstract][Full Text] [Related]
15. Oncofetal protein glypican-3 distinguishes yolk sac tumor from clear cell carcinoma of the ovary.
Esheba GE; Pate LL; Longacre TA
Am J Surg Pathol; 2008 Apr; 32(4):600-7. PubMed ID: 18277882
[TBL] [Abstract][Full Text] [Related]
16. Can CD34 discriminate between benign and malignant hepatocytic lesions in fine-needle aspirates and thin core biopsies?
de Boer WB; Segal A; Frost FA; Sterrett GF
Cancer; 2000 Oct; 90(5):273-8. PubMed ID: 11038423
[TBL] [Abstract][Full Text] [Related]
17. Upregulation of Glypican-3 expression in hepatocellular carcinoma but downregulation in cholangiocarcinoma indicates its differential diagnosis value in primary liver cancers.
Man XB; Tang L; Zhang BH; Li SJ; Qiu XH; Wu MC; Wang HY
Liver Int; 2005 Oct; 25(5):962-6. PubMed ID: 16162153
[TBL] [Abstract][Full Text] [Related]
18. Arginase-1 is a more sensitive marker of hepatic differentiation than HepPar-1 and glypican-3 in fine-needle aspiration biopsies.
Fujiwara M; Kwok S; Yano H; Pai RK
Cancer Cytopathol; 2012 Aug; 120(4):230-7. PubMed ID: 22434791
[TBL] [Abstract][Full Text] [Related]
19. Glypican-3 expression is correlated with poor prognosis in hepatocellular carcinoma.
Shirakawa H; Suzuki H; Shimomura M; Kojima M; Gotohda N; Takahashi S; Nakagohri T; Konishi M; Kobayashi N; Kinoshita T; Nakatsura T
Cancer Sci; 2009 Aug; 100(8):1403-7. PubMed ID: 19496787
[TBL] [Abstract][Full Text] [Related]
20. Glypican-3 protein expression in primary and metastatic melanoma: a combined immunohistochemistry and immunocytochemistry study.
Kandil D; Leiman G; Allegretta M; Evans M
Cancer; 2009 Aug; 117(4):271-8. PubMed ID: 19517479
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
